Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound mannitol injection

A mannitol and injection technology, applied in the field of compound mannitol injection, can solve the problems of unsatisfactory solubilization effect, large vascular irritation, weak dehydration effect, etc. Effect of Crystallization Chance

Active Publication Date: 2015-12-16
GUANGXI YUYUAN PHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the crystallization probability of mannitol glucose injection is extremely low, it is not suitable for diabetic patients, and its dehydration effect is weaker than that of ordinary mannitol injection; compound mannitol may also have the same disadvantages as other injection drugs: there may be Higher incidence of allergies, and it is a hypertonic solution with high drug concentration and greater irritation to blood vessels. Most patients have obvious pain during intravenous infusion
In addition, improving the formula of mannitol injection and improving the crystallization of mannitol can also be achieved by adding co-solvents and other excipients, but generally the excipients with better solubilization are less safe, while the excipients with better safety have a solubilizing effect not ideal
From this point of view, mannitol injections with good curative effect and high safety without crystallization at low temperature are still very limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound mannitol injection
  • Compound mannitol injection
  • Compound mannitol injection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] A compound mannitol injection is made from the following raw materials in percentage by weight:

[0020]

[0021] The preparation method of compound mannitol injection: take mannitol, sorbitol, olive oil, sodium chloride and Tween 80 and dissolve in appropriate amount of water for injection; add 0.2% W / V activated carbon for needles, heat to boil, filter; add The remaining amount of water for injection is mixed evenly, filtered, filled and sealed, and sterilized by autoclaving at 121°C for 15 minutes to obtain the product.

Embodiment 2

[0023] A compound mannitol injection is made from the following raw materials in percentage by weight:

[0024]

[0025] The preparation method of compound mannitol injection: take mannitol, sorbitol, olive oil, sodium chloride and Tween 80 and dissolve in an appropriate amount of water for injection; add 0.3% W / V activated carbon for needles, heat to boil, filter; add The remaining amount of water for injection is mixed evenly, filtered, filled and sealed, and sterilized by autoclaving at 121°C for 15 minutes to obtain the product.

Embodiment 3

[0027] A compound mannitol injection is made from the following raw materials in percentage by weight:

[0028]

[0029] The preparation method of compound mannitol injection: take mannitol, sorbitol, olive oil, sodium chloride and Tween 80 and dissolve in appropriate amount of water for injection; add 0.1% W / V activated carbon for needles, heat to boil, filter; add The remaining amount of water for injection is mixed evenly, filtered, filled and sealed, and sterilized by autoclaving at 121°C for 15 minutes to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of pharmaceutic preparations, in particular to compound mannitol injection. The compound mannitol injection is prepared from, by weight, 6-10% of mannitol, 3-9% of sorbitol, 1-6% of Tween 80, 1-5% of olive oil, 0.4-0.6% of sodium chloride and the balance injection water. The compound mannitol injection is good in treatment effect, does not crystallize at low temperatures, is high in using safety performance, can not cause allergies, can be used conveniently clinically, and is capable of reducing adverse reactions including infusion reactions remarkably.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a compound mannitol injection. Background technique [0002] Mannitol is a kind of hexanehexol, which is an isomer of sorbitol. It is a good diuretic and dehydrating drug. It is used to treat cerebral edema and increased intracranial pressure caused by various reasons. It is also used in other eye-reducing diseases. When internal pressure medicine is ineffective or before intraocular surgery. At 20°C, the solubility of mannitol in water is 1:5.5 (18%), and 20% mannitol injection is a supersaturated solution. When the room temperature is lower than 15°C, mannitol particles are easily produced, and even crystals are precipitated. When the temperature continues to drop, the crystals increase in size and become large columnar and flocculent crystals. If the packaging is a plastic soft bag, it will cause damage and increase the risk of medication. The particles i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K31/047A61K47/44A61K47/26A61K47/22A61K47/04A61P7/10
Inventor 庞春林罗世东王亚军陈兴华廖柳艳王敏
Owner GUANGXI YUYUAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com